LOS GATOS, Calif., Sept. 27, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. ( Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that due to adverse market conditions, it has withdrawn its proposed public offering of shares of its common stock.
Read more at prnewswire.comAridis Pharmaceuticals Announces Withdrawal of Public Offering of Common Stock
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here